Physiologic model for the pharmacokinetics of 2′deoxycoformycin in normal and leukemic mice
- 1 October 1981
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Biopharmaceutics
- Vol. 9 (5) , 519-534
- https://doi.org/10.1007/bf01061024
Abstract
A flow-limited physiologic mathematical model has been developed to describe the time course of 2′deoxycoformycin (2′dCF) concentrations in the plasma and tissues of mice following iv and ip doses. Urinary excretion is modeled as a linear process involving filtration and secretion, since kidney clearance exceeded estimated glomerular filtration rate. Intracellular binding is described as the sum of linear nonspecific binding plus strong saturable binding to adenosine deaminase. Pharmacokinetic parameters are determined by a sequential optimization scheme in which each tissue is studied by means of a hybrid model. The model has been used to predict pharmacokinetic behaviour of 2′dCF in both normal and leukemic mice, and model simulations are compared with published data.Keywords
This publication has 22 references indexed in Scilit:
- Physiological pharmacokinetics: An in vivo approach to membrane transportPharmacology & Therapeutics, 1980
- Preliminary model for streptozocin metabolism in miceJournal of Pharmaceutical Sciences, 1980
- A review of the applications of physiologically based pharmacokinetic modelingJournal of Pharmacokinetics and Biopharmaceutics, 1979
- INHIBITION OF ADENOSINE DEAMINASE BY CO-VIDARABINE AND ITS EFFECT ON THE METABOLIC DISPOSITION OF ADENINE ARABINOSIDE (VIDARABINE)Annals of the New York Academy of Sciences, 1977
- Tight-binding inhibitors—IV. Inhibition of adenosine deaminases by various inhibitorsBiochemical Pharmacology, 1977
- Enhancement of the Biological Activity of Adenosine Analogs by the Adenosine Deaminase Inhibitor 2’-DeoxycoformycinPharmacology, 1977
- The kinetics of methotrexate distribution in spontaneous canine lymphosarcomaJournal of Pharmacokinetics and Biopharmaceutics, 1975
- A novel adenosine and ara‐a deaminase inhibitor, (R)‐3‐(2‐deoxy‐β‐D‐erythro‐pentofuranosyl)‐3,6,7,8‐tetrahydroimidazo[4,5 ‐d] [1,3]diazepin‐8‐olJournal of Heterocyclic Chemistry, 1974
- Pharmacokinetics of 1-β-d-arabinofuranosylcytosine (Ara-C) deamination in several speciesBiochemical Pharmacology, 1973
- Methotrexate PharmacokineticsJournal of Pharmaceutical Sciences, 1971